Why Stem Cell Therapy?
Dr. Bryn J. Henderson (DO, JD, FACPE, CIME) is visionary physician executive leading RMG. In this amazing education video, he is explaning clearly why patients should choose Stem Cell Therapy...

By: iManifestart

View original post here:
Why Stem Cell Therapy? - Video

Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage - 6 Months After Stemcell Transplant
Bruce from Perth Australia give us an update 6 Months After his cord Mesenchymal stem cell treatment for Iiver cirrhosis, kidney complications in Thailand: More here: http://stemcellthailand.org/th...

By: Regeneration Center of Thailand

Here is the original post:
Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage - 6 Months After Stemcell Transplant - Video

Ryan Benton Discusses Stem Cell Therapy for Duchenne #39;s Muscular Dystrophy
Ryan Benton is the first patient in the United States to receive human umbilical cord-derived mesenchymal stem cell therapy for Duchenne #39;s muscular dystrophy...

By: http://www.cellmedicine.com

Read the original:
Ryan Benton Discusses Stem Cell Therapy for Duchenne's Muscular Dystrophy - Video

Posted by Richard Dietman (@rdietman) 3 day(s) ago

Mayo Clinic Radio: Cardiac Regeneration/Stop-Smoking Drug/Juicing

On this weeks Mayo Clinic Radio,fixing a broken heart. Cardiac regeneration uses the bodys own stem cells to repair damage done by heart disease. Mayo Clinic cardiologist Dr. Atta Behfar explains. Also on the program, nicotine dependency expert Dr. Richard Hurt discusses results of a new study about the stop-smoking drug varenicline (Chantix). And Mayo Clinic registered dietitian Katherine Zeratsky explains the risks of juice-only diets.

Myth or Matter-of-Fact: Cardiac regeneration may someday replace the need for surgery to repair heart damage.

To listen to the program at 9 a.m. Saturday, February 21, clickhere.

Follow#MayoClinicRadioand tweet your questions.

Mayo Clinic Radio is available oniHeartRadio.

Mayo Clinic Radiois a weeklyone-hour radio program highlighting health and medical informationfrom Mayo Clinic.

To find and listen toarchived shows,click here.

Read this article:
Mayo Clinic Radio: Cardiac Regeneration/Stop-Smoking Drug/Juicing

Under normal conditions, many of the different types of tissue-specific adult stem cells, including hematopoietic stem cells, exist in a state or dormancy where they rarely divide and have very low energy demands. "Our theory was that this state of dormancy protected hematopoietic stem cells from DNA damage and therefore protects them from premature aging," says Dr. Michael Milsom, leader of the study.

However, under conditions of stress, such as during chronic blood loss or infection, hematopoietic stem cells are driven into a state of rapid cell division in order to produce new blood cells and repair the damaged tissue. "It's like forcing you out of your bed in the middle of the night and then putting you into a sports car and asking you to drive as fast as you can around a race circuit while you are still half asleep," explains Milsom. "The stem cells go from a state of rest to very high activity within a short space of time, requiring them to rapidly increase their metabolic rate, synthesize new DNA and coordinate cell division. Suddenly having to simultaneously execute these complicated functions dramatically increases the likelihood that something will go wrong."

Indeed, experiments described in the study show that the increased energy demands of the stem cells during stress result in elevated production of reactive metabolites that can directly damage DNA. If this happens at the same time that the cell is trying to replicate its DNA, then this can cause either the death of the stem cell, or potentially the acquisition of mutations that may cause cancer.

Normal stem cells can repair the majority of this stress-induced DNA damage, but the more times you are exposed to stress, the more likely it is that a given stem cell will inefficiently repair the damage and then die or become mutated and act as a seed in the development of leukemia. "We believe that this model perfectly explains the gradual accumulation of DNA damage in stem cells with age and the associated reduction in the ability of a tissue to maintain and repair itself as you get older," Milsom adds.

In addition, the study goes on to examine how this stress response impacts on a mouse model of a rare inherited premature aging disorder that is caused by a defect in DNA repair. Patients with Fanconi anemia suffer a collapse of their blood system and have an extremely high risk of developing cancer. Mouse models of Fanconi anemia have exactly the same DNA repair defect as found in human patients but the mice never spontaneously develop the bone marrow failure observed in nearly all patients.

"We felt that stress induced DNA damage was the missing ingredient that was required to cause hematopoietic stem cell depletion in these mice," says Milsom. When Fanconi anemia mice were exposed to stimulation mimicking a prolonged viral infection, they were unable to efficiently repair the resulting DNA damage and their stem cells failed. In the same space of time that normal mice showed a gradual decline in hematopoietic stem cell numbers, the stem cells in Fanconi anemia mice were almost completely depleted, resulting in bone marrow failure and an inadequate production of blood cells to sustain life.

"This perfectly recapitulates what happens to Fanconi anemia patients and now gives us an opportunity to understand how this disease works and how we might better treat it," commented Milsom.

Prof. Dr. Andreas Trumpp, director of HI-STEM and head of the Division of Stem Cells and Cancer at the DKFZ believes that this work is a big step towards understanding a range of age-related diseases. "The novel link between physiologic stress, mutations in stem cells and aging is very exciting," says Trumpp, a co-author of the study. "By understanding the mechanism via which stem cells age, we can start to think about strategies to prevent or at least reduce the risk of damaged stem cells which are the cause of aging and the seed of cancer."

Story Source:

The above story is based on materials provided by German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). Note: Materials may be edited for content and length.

Read more:
A good night's sleep keeps your stem cells young

Contact Information

Available for logged-in reporters only

Newswise MINNEAPOLIS Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

The study involved 21 people whose disability due to MS had increased during the previous year even though they were taking conventional medications (also known as first-line treatments). The participants, who were an average age of 36, were at an average disability level where a cane or crutch was needed to walk.

In MS, the bodys immune system attacks its own central nervous system. In this phase II study, all of the participants received medications to suppress immune system activity. Then 12 of the participants received the MS drug mitoxantrone, which reduces immune system activity. For the other nine participants, stem cells were harvested from their bone marrow. After the immune system was suppressed, the stem cells were reintroduced through a vein. Over time, the cells migrate to the bone marrow and produce new cells that become immune cells. The participants were followed for up to four years.

This process appears to reset the immune system, said study author Giovanni Mancardi, MD, of the University of Genova in Italy. With these results, we can speculate that stem cell treatment may profoundly affect the course of the disease.

Intense immunosupression followed by stem cell treatment reduced disease activity significantly more than the mitoxantrone treatment. Those who received the stem cell transplants had 80 percent fewer new areas of brain damage called T2 lesions than those who received mitoxantrone, with an average of 2.5 new T2 lesions for those receiving stem cells compared to eight new T2 lesions for those receiving mitoxantrone.

For another type of lesion associated with MS, called gadolinium-enhancing lesions, none of the people who received the stem cell treatment had a new lesion during the study, while 56 percent of those taking mitoxantrone had at least one new lesion.

Mancardi noted that the serious side effects that occurred with the stem cell treatment were expected and resolved without permanent consequences.

More research is needed with larger numbers of patients who are randomized to receive either the stem cell transplant or an approved therapy, but its very exciting to see that this treatment may be so superior to a current treatment for people with severe MS that is not responding well to standard treatments, Mancardi said.

Read this article:
Stem Cell Transplants May Work Better than Existing Drug for Severe Multiple Sclerosis

9 hours ago Inside the cell, calcium ions are released from a structure called the endoplasmic reticulum (ER). Forces applied to the bead cause ion channels in the ER to open mechanically (shown in red above), rather through biochemical signaling chemically (shown in green below). Credit: Jie Sun/UC San Diego

After using optical tweezers to squeeze a tiny bead attached to the outside of a human stem cell, researchers now know how mechanical forces can trigger a key signaling pathway in the cells.

The squeeze helps to release calcium ions stored inside the cells and opens up channels in the cell membrane that allow the ions to flow into the cells, according to the study led by University of California, San Diego bioengineer Yingxiao Wang.

Researchers have known that mechanical forces exerted on stem cells have a significant role to play in how the cells produce all kinds of tissuesfrom bone to bloodfrom scratch. But until now, it hasn't been clear how some of these forces translate into the signals that prod the stem cells into building new tissue.

The findings published in the journal eLife could help scientists learn more about "the functional mechanisms behind stem cell differentiation," said Wang, an associate professor of bioengineering. They may also guide researchers as they try to recreate these mechanisms in the lab, to coax stem cells into developing into tissues that could be used in transplants and other therapies.

"The mechanical environment around a stem cell helps govern a stem cell's fate," Wang explained. "Cells surrounded in stiff tissue such as the jaw, for example, have higher amounts of tension applied to them, and they can promote the production of harder tissues such as bone."

Stem cells living in tissue environments with less stiffness and tension, on the other hand, may produce softer material such as fat tissue.

Wang and his colleagues wanted to learn more about how these environmental forces are translated into the signals that stem cells use to differentiate into more specialized cells and tissues. In their experiment, they applied force to human mesenchymal stem cellsthe type of stem cells found in bone marrow that transform into bone, cartilage and fat.

The engineers used a highly focused laser beam to trap and manipulate a tiny bead attached to the cell membrane of a stem cell, creating an optical "tweezers" to apply force to the bead. The squeeze applied by the tweezers was extremely smallon the order of about 200 piconewtons. (Forces are measured in a unit called newtons; one newton is about the weight of an apple held to the Earth by gravity, and one piconewton is equivalent to one-trillionth of a newton.)

When there were no calcium ions circulating outside the cell, this force helped to release calcium ions from a structure inside the cell called the endoplasmic reticulum. The release is aided by the cell's inner structural proteins called the cytoskeleton, along with contracting protein machinery called actomyosin. When the force triggered the movement of calcium ions into the cell from its extracellular environment, only the cytoskeleton was involved, the researchers noted.

Continue reading here:
Engineers put the 'squeeze' on human stem cells

Advanced stem cell treatments instead of surgery - Denver Regenerative Medicine
If you #39;re tired of treating a chronic injury with prescription drugs, and you #39;ve been told surgery is your next option, there may be a different treatment for you. Dr. Joel Cherdack of...

By: Denver Regenerative Medicine

Read the original post:
Advanced stem cell treatments instead of surgery - Denver Regenerative Medicine - Video

Contact Information

Available for logged-in reporters only

Newswise The governing board of the California Institute for Regenerative Medicine (CIRM) has awarded two University of California, San Diego researchers almost $3 million in combined funding to pursue new technologies intended to accelerate advances moving stem cell therapies out of the lab and into the clinic.

The funding was part of almost $30 million in new Tools and Technologies awards announced at CIRMs monthly meeting in San Francisco.

Sometimes even the most promising therapy can be derailed by a tiny problem, said Jonathan Thomas, JD, PhD, chair of the CIRM Board. These awards are designed to help find ways to overcome those problems, to bridge the gaps in our knowledge and ensure that the best research is able to keep progressing and move out of the lab and into clinical trials in patients.

Shaochen Chen, PhD, professor in the Department of Nanoengineering in the Jacobs School of Engineering and a member of the Institute of Engineering in Medicine at UC San Diego, received a $1.3 million in CIRM funding for development of 3D bioprinting techniques using human embryonic stem cell-derived heart muscle cells to create new cardiac tissue.

Millions of Americans suffer from cardiovascular disease, specifically congestive heart failure in which a heart valve ceases to work properly. Current treatment often calls for a valve transplant, but donor availability does not meet need.

Chen and colleagues are exploring the possibility of engineering healthy cardiac tissues bioprinted from heart muscle cells, called cardiomyocytes, created from human embryonic stem cells. These tissues could then be implanted in a damaged heart, restoring function.

Shyni Varghese, PhD, associate professor in the Department of Bioengineering at the Jacobs School of Engineering and director of the Bio-Inspired Materials and Stem Cell Engineering Laboratory, received a $1.4 CIRM grant to improve in vivo function of transplanted stem cells.

Vargheses lab focuses upon the complex interactions of cells with their surrounding microenvironment, and how the conditions necessary to promote normal, healthy survival and growth occur.

More here:
Two UC San Diego Scientists Receive Stem Cell Technology Grants

TAMPA Dr. Burton Feinerman has spent more than a decade using stem cell therapies that are banned in the United States, sending desperate families to Peru seeking treatments for their babies' terminal conditions like Tay-Sachs disease.

The therapies are costly and unproven, and no insurer will cover them. But there is no law against a U.S. doctor recommending them, as long as they aren't performed here.

Now the 85-year-old pediatrician is focusing on a stem cell therapy he can perform in Tampa, for seniors with such incurable lung conditions as chronic obstructive pulmonary disease, or COPD.

Feinerman, medical director of the Tampa-based Lung Institute, says lung patients tend to get the most benefit from stem cell therapies. And he can treat them in the United States because he is re-infusing patients with their own stem cells, a legal process under certain circumstances.

But it's not approved as a lung disease therapy in this country. Neither the American Lung Association nor the International Society for Stem Cell Research have endorsed it. Medicare won't cover it.

So Feinerman's patients must pay cash between $7,500 and $12,000 for a three-day treatment, plus $4,500 for additional "boosters'' of cells extracted from their blood or abdominal fat.

The Lung Institute has produced a slick website and an advertising campaign, and it puts on seminars at which prospects can hear the testimonials of satisfied patients.

But there are no clinical data showing stem cell therapies benefit patients with lung disease, said Dr. Daniel Weiss, a professor at the University of Vermont College of Medicine and a leading lung disease researcher. Further, studies of mice suggest that if the therapies work, it likely would help only acute lung conditions like respiratory distress syndrome, not chronic conditions like COPD.

"I do not recommend any type of cell therapy (for lung disease) at this point," Weiss said.

Feinerman insists the doubters are wrong. "Just go to Google," he told a Times reporter who asked him for clinical research to back his claims. Lung Institute employees later provided citations for three journal articles, but none showed the treatments worked. In fact, Weiss wrote two of the articles.

Continued here:
Tampa stem cell clinic is long on promises, not evidence

Boston, MA (PRWEB) January 29, 2015

Dr. James Sherley, Director of the new biotech start-up Asymmetrex, LLC (formerly known as The Adult Stem Cell Technology Center, LLC) is looking forward to four upcoming opportunities in 2015 to continue to impress both academic and industry audiences with his companys very frank take on what is needed to accelerate progress in stem cell medicine.

Asymmetrex has set the focus for its efforts on adult stem cells that are found in the organs and tissues of children and adults. Unlike human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), adult stem cells are free of induced mutations, are not tumor-forming, and have the essential ability to continuously regenerate mature human tissue cells like those in children and adults. To date, hESCs and iPSCs have only been able to regenerate immature cells, and even those not continuously.

Previously, the two main challenges hindering wider use of adult stem cells for drug development and medical therapies have been difficulty producing them and difficulty counting them. Asymmetrex has reported, and in many cases secured patents for, new technologies that reduce or eliminate both of these challenges. At the coming conferences, Dr. Sherley will describe the companys most recent technological advances in this regard and discuss the science that led to them.

In particular, he will highlight the companys newest technology developed with partner AlphaSTAR Corporation for estimating adult stem cell number in any human tissue. The two companies are developing the new technology as an assay to detect drug candidates that will fail in expensive pre-clinical animal studies and clinical trials because of intolerable toxicity against tissue stem cells. By screening-out such drugs earlier in the drug development process, Asymmetrex and AlphaSTAR estimate that together they could save the U.S. pharmaceutical industry $4-5 billion each year.

The four scheduled conferences include the 7th Annual Predictive Toxicology Summit, February 16-18, in London; the 5th World Congress on Cell and Stem Cell Research, March 23-25, in Chicago; the 2015 Annual Meeting at Experimental Biology, March 28-April 1, in Boston; and the Inaugural 3D Cellular Models Conference, June 11-12, also in Boston.

The breadth of conference topics reflects the many important roles that adult tissue stem cells play in human biology and cellular medicine. Dr. Sherley offers that, Because of the importance of adult stem cells in normal body function, it is not surprising that Asymmetrexs technologies impact so many different facets of stem cell biology, regenerative medicine, and drug development.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read this article:
Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult ...

Hair growing from human dermal papillae cells, which were cultivated from pluripotent stem cells.

Cells needed to grow hair have been produced from human stem cells, according to a study led by scientists at the Sanford-Burnham Medical Research Institute in La Jolla. The first-time feat could uncork a bottleneck in developing hair-replacement therapies, the scientists say.

Called the dermal papillae, these cells regulate hair follicle formation and growth cycles. They rapidly lose their hair-generating ability after being grown outside the body, limiting their use for hair regrowth. Another cell type derived from stem cells effectively substitutes for the dermal papillae, the scientists found.

These artificial dermal papillae cells were grown from pluripotent stem cells, which can be derived either from human embryos or a patient's own skin cells. The latter, called induced pluripotent stem cells, are of the most interest, said lead researcher Alexey V. Terskikh. Patients can donate their own IPS cells, which can be grown into the replacement dermal papillae in "unlimited" quantities," he said.

Alexey V. Terskikh, Principal Investigator, Sanford-Burnham Medical Research Institute / Sanford-Burnham Medical Research Institute

Sanford-Burnham is now looking for business partners to commercialize the discovery. More information can be found at: utsandiego.com/sbhair.

The study was published last week in the journal PLOS One. Terskikh is the study's senior author. Ksenia Gnedeva is first author.

In the lab, the human embryonic stem cells were first turned into neural crest cells, which produce brain cells, cartilage, bone, pigment and muscle cells. The cells were then converted into the artificial dermal papillae cells. These human cells induced hair formation, when transplanted along with mouse skin epidermal cells into immune-deficient and nearly hairless "nude mice".

Because nude mice were created from albino ancestors, the transplanted skin cells were chosen from dark-haired mice. This let the scientists distinguish hairs grown by the mice from cells grown by the transplanted cells.

Transplanted epidermal cells alone caused "minimal" growth, the study said.

Continue reading here:
Sanford-Burnham's hair-raising study

ELK GROVE (CBS13) Hes only 17, but hes already making big waves in the science community.

A local high school senior was selected as a semi-finalist in the 2015 Intel Science Talent Search. His research on stem cells set him apart from the rest. Out of hundreds of applicants, Ryan Fong, a senior at Sheldon High School in Elk Grove, is being recognized for his research in stem cells. Its an opportunity he says he wont soon forget.

Each of these cells is genetic material from one cell, he explains.

He doesnt come from a line of doctors or medical researchers. Fong is just a teenager interested in stem cells.

Its such a young field and it holds so much potential to redefine what we think is medically possible, he says.

Fong wasnt always intrigued by science, but a couple of years ago, at the request of a teacher, he decided to enter the Teen Biotech Challenge and happened to win an internship at the UC Davis School of Medicine.

I didnt know anything about research and I didnt know what I was getting into, but I dived in head first, said Fong.

That internship became a launching pad for Fong. He was published in a medical peer review journal called Stem Cells. And this past summer, he spent his time in Stanford among doctors and researchers working on reprogramming cells from a layer of skin so that it can match any cell type in the body.

So were taking someones cells from their skin and turning them into cells that can be found in the lungs, said Fong.

Their research on the topic won Fong a spot as a semi-finalist in the 2015 Intel Science Talent Search, and a $1,000 scholarship.

Read more from the original source:
Local Teen Selected As Semi-Finalist In Intel Science Talent Search

"She #39;s Happy" RMG #39;s next Stem Cell Miracle
Meet Mary Taylor, she was blind for four years from wet and dry Macular Degeneration. Her son Richard, was a previous patient of Regenerative Medical Group, as he received treatment for his...

By: iManifestart

Read the original here:
"She's Happy" RMG's next Stem Cell Miracle - Video

20 hours ago

Transcription factor Twist1 is involved in many processes where cells change shape or function. Thereby, Twist1 is crucial for embryonic development, but has also been implicated in cancer progression. However, the precise contribution of Twist1 to these processes is under much debate. Scientists from the Helmholtz Zentrum Mnchen describe a new mode of action: a short-term, transient activation of Twist1 primes cells for stem cell-like properties. By contrast, prolonged, chronic Twist1 activity suppresses stem cell-like traits. These results, published in the journal Cell Reports, help to unravel seemingly contradictory observations and illuminate the complexities of transcription factor action in regeneration and tumor progression.

Team leader Christina Scheel summarizes the results: "Twist1 is a developmental master regulator that has also been implicated in cancer progression. We show that transient Twist1 activation primes certain cells for stem-cell-like properties and cellular plasticity. Said differently, induction of these traits depends on Twist1, but they are only displayed by the cells after Twist1 deactivation. By contrast, chronic Twist1 activity suppresses stem-cell-like properties and promotes a phenotype that is characterized by extreme changes in cell shape and function, effectively locking the cells into an invasive, non-proliferative phenotype. Thereby, our results provide an integrative view of seemingly contradictory results concerning the effects of Twist1 in physiological and pathological processes."

Duration of Twist1 activity decisive

Scientists from the Institute of Stem Cell Research and the Institute of Experimental Genetics at the Helmholtz Zentrum Mnchen (HMGU) examined the effects of Twist1 activation on breast epithelial cells, paying particular attention to the duration of the Twist1-signal. To their surprise, cells were permanently altered after a short dose of Twist1-activation: they proliferated under very stringent conditions usually permissive only for stem cells and were able to generate complex multicellular structures, suggesting a gain of cellular plasticity.

Twist1 may fuel regeneration

A high level of plasticity implies regenerative potential. However, when activated during tumor development, Twist1 promotes aggressive behaviour in tumor cells. With their investigations, the team was able to reveal a new aspect of how Twist1 regulates cell shape and function and, thereby, impacts regeneration, but also tumor progression.

"Our results offer important insights for further mechanistic studies of regeneration in healthy and tumour cells", explains first author Johanna Schmidt. "The precise delineation of the different modes of action by Twist1 provide the basis for future studies aiming to manipulate its activity either to promote regeneration or target advanced tumors ," adds co-author Elena Panzilius.

Explore further: New mechanism involved in skin cancer initiation, growth and progression

More information: Schmidt, J. et al. (2015), Stem-Cell-like Properties and Epithelial Plasticity Arise as Stable Traits after Transient Twist1 Activation, Cell Reports, DOI: 10.1016/j.celrep.2014.12.032

See original here:
Twist1: Complex regulator of cell shape and function

Stem cell therapy may have helped patients with a form of multiple sclerosis, according to a preliminary study.

Patients with relapsing-remitting multiple sclerosis showed signs of improvement after being treated with their own, or autologous "nonmyeloablative hematopoietic stem cells," a class of blood-forming stem cells, the study found. It was published Tuesday in the Journal of the American Medical Association.

Half, or 41 patients, tested two years after treatment experienced significant improvement on the Expanded Disability Status Scale, a measure of disability. And of patients tested at 4 years, 23, or 64 percent, showed significant improvement. Four-year relapse-free survival was 80 percent and progression-free survival was 87 percent.

"To our knowledge, this is the first report of significant and sustained improvement in the EDSS score following any treatment for MS," stated the study. It was led by Dr. Richard K. Burt of Northwestern University in Chicago.

However, only limited conclusions can be drawn from the uncontrolled study, according to scientists who examined the results. While the therapy was associated with improvement, the stem cell transplant may not have been key. A conditioning regimen that partially depleted the stem cells before transplantation may have been responsible, said Dr. Stephen L. Hauser in a JAMA article accompanying the study.

"According to Carl Sagan, 'extraordinary claims require extraordinary evidence,' a standard that is not always met in this report, and not claimed by the authors. Even though the authors appropriately acknowledge many of the limitations associated with their case series, their statement that 'to our knowledge, this is the first report of significant and sustained improvement in the EDSS score following any treatment for MS' could be challenged," Hauser wrote.

Jeanne Loring, a stem cell researcher who studies multiple sclerosis and other neurodegenerative diseases, agreed that the results are far from conclusive.

"Multiple sclerosis is an autoimmune disease, meaning that the patients' own immune cells attack their own nervous systems," Loring said by email after examining the study. "The authors of the JAMA article treated MS patients with their own blood stem cells in the hope that these cells would replace some of the self-destructive immune cells."

However, the uneven course of MS makes it hard to draw conclusions, wrote Loring, who heads the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla.

"Most patients with MS have attacks, followed by recovery, followed by another attack. In a few of these patients, the blood stem cell treatment seemed to extend their time between attacks. It's important to understand that other treatments, including drugs, have shown similar modest improvements, so it's too soon to celebrate a stem cell therapy."

Visit link:
MS patients given stem cells improve

(Tokyo-AFP) - Japanese scientists say they are on their way to being able to create custom-made skin, bone and joints using a 3D printer.

Several groups of researchers around the world have developed small masses of tissue for implants, but now they are looking to take the next step and make them functional.

Tsuyoshi Takato, a professor at the University of Tokyo Hospital, said his team had been working to create "a next-generation bio 3D printer", which would build up thin layers of biomaterials to form custom-made parts.

His team combines stem cells -- the proto-cells that are able to develop into any body part -- and proteins that trigger growth, as well as synthetic substance similar to human collagen.

Using a 3D printer, they are working on "mimicking the structure of organs" -- such as the hard surface and spongy inside for bones, Takato said.

In just a few hours, the printer crafts an implant using data from a Computer Tomography (CT) scan.

These implants can fit neatly into place in the body, and can quickly become assimilated by real tissue and other organs in the patient, the plastic surgeon said.

"We usually take cartilage or bone from the patient's own body (for regular implants), but these custom-made implants will mean not having to remove source material," Takato said.

The technology could also offer hope for children born with bone or cartilage problems, for whom regular synthetic implants are no good because of the rate of their body's growth.

The main hurdle was the heat generated by conventional 3D printers, which damages living cells and protein.

Read the original post:
Japan researchers target 3D-printed body parts

Live100 Hospitals - Stem Cell Therapy
"We wanted to focus on stem cell after seeing the advantages since the cells were available in the body and they were really doing wonderful research across the world which was really promising...

By: Live100 Hospitals

Continued here:
Live100 Hospitals - Stem Cell Therapy - Video

How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell
http://www.nextgenerationstemcell.com Stem Cell Therapy Stem Cell Research.

By: Jasen Kobobel

The rest is here:
How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell - Video

Researchers have successfully improved the ability of muscle to repair itself - by artificially increasing levels of the BMI1 gene in the muscle-specific stem cells of mice with muscular dystrophy.

The BMI1 gene has been previously linked to the body's ability to regenerate tissue cells in areas such as blood or skin.

Led by Queen Mary University of London and published in the Journal of Experimental Medicine, the study provides the first proof of concept that manipulating the activity of this gene enhances the regeneration of the dystrophic muscle to a level where strength is visibly improved. For example, the mice were able to run on a treadmill for a longer time period and at a faster pace.

This line of research will now be further developed and scientists aim to one day apply the treatment to patients with chronic muscle wasting such as muscular dystrophy.

Muscular dystrophy is a devastating and incurable condition. Duchenne Muscular Dystrophy - the deadliest form of the muscle-wasting disease - is caused by mutations in a gene which eventually cause muscle fibres to become damaged and waste away.

Duchenne Muscular Dystrophy is characterised by repeated cycles of muscle damage and repair, resulting in exhaustion of the muscle repair cells. It affects one in 3,500 boys and normally proves fatal by early adulthood.

Professor Silvia Marino, Lead Author, Queen Mary University of London, comments: "This study has given us the first 'proof of concept' that harnessing the gene BMI1 can significantly enhance the regeneration of dystrophic muscles to a level where strength is visibly improved. We plan to continue our research and hope to establish whether this concept can be successfully applied to patients with muscular dystrophy, but possibly other degenerative conditions or even traumatic muscle damage."

###

This research was funded by the MRC and the charity Muscular Dystrophy Campaign.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more here:
Hope for muscular dystrophy patients: Harnessing gene helps repair muscle damage